 NEW HAVEN, Conn., Oct. 7, 2021 PRNewswire -- Trevi Therapeutics, Inc. Nasdaq: TRVI, a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy HaduvioTM nalbuphine ER to treat serious neurologically mediated conditions, today announced that senior management will be available for virtual one-on-one meetings at Alliance Global Partners Virtual Biotech Specialty Pharma Conference taking place October 13, 2021. 